The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers

Int J Biol Sci. 2022 May 16;18(8):3498-3527. doi: 10.7150/ijbs.70447. eCollection 2022.

Abstract

Cancers are generally recognized as the leading cause of death and a predominant barrier to prolonging life expectancy in both developed and developing countries. Emodin is a typical anthraquinone derivative from various plants that exhibits a wide spectrum of biological activities, such as anticancer, antibacterial, hepatoprotective and anti-inflammatory activities. Much previous preclinical evidence has demonstrated that emodin exhibits reliable effects on several cancer types, including lung cancer, liver cancer, colon cancer, breast cancer, pancreatic cancer, leukemia, cervical cancer, and ovarian cancer, etc. The related molecular mechanisms corresponding to the anticancer activities of emodin are involved in the induction of apoptosis, inhibition of cell proliferation, enhanced reactive oxygen species (ROS) accumulation, and induction of autophagy, etc. In the present review, we summarized the sources, anticancer properties in vitro and in vivo, molecular mechanisms, metabolic transformation and toxicities of emodin. In addition, we also discussed the limitations of the present investigations of emodin against cancers and gave some perspectives for them, which would be beneficial for the further exploration and development of this natural compound as a clinical cancer drug.

Keywords: Apoptosis; Autophagy; Cycle arrest; Drug resistant; Emodin; Metastasis and invasion.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anthraquinones / pharmacology
  • Anthraquinones / therapeutic use
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Apoptosis
  • Colonic Neoplasms*
  • Emodin* / pharmacology
  • Emodin* / therapeutic use
  • Humans

Substances

  • Anthraquinones
  • Antineoplastic Agents
  • Emodin